Alpha-fetoprotein

Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023

The ASCO meeting will take place in Chicago from June 2-6, 2023.

Key Points: 
  • The ASCO meeting will take place in Chicago from June 2-6, 2023.
  • Now across multiple tumor models, we have observed high activity in treatment groups including statistically significant dose-dependent reduction in tumor volume and increased survival.
  • The research used an ovarian xenograft model compared to control with four dosing regimens of the AFP-maytansine conjugate, ACT-903.
  • ACT plans to submit an Investigational New Drug (IND) application for ACT-903 in 2024.

Alpha Cancer Technologies (ACT) Publishes Pre-Clinical Study Results in Cancer Cell International Demonstrating Excellent Safety and Significant Anti-Tumor Activity from the Company’s Next Generation ADC, ACT-903

Retrieved on: 
Thursday, April 6, 2023

Human AFP acts as a shuttle protein, transporting a variety of molecules including targeted anti-cancer agents inside the cell via the AFP receptor.

Key Points: 
  • Human AFP acts as a shuttle protein, transporting a variety of molecules including targeted anti-cancer agents inside the cell via the AFP receptor.
  • Studies were performed to investigate the use of ACT-101 conjugated with maytansine for targeted toxin delivery to cancer.
  • A significant reduction of tumor burden compared to control was achieved in the 40 and 50 mg/kg dose groups.
  • The observed efficacy and excellent tolerability of ACT-903 in these xenograft models support advancing the development of ACT-903 into clinical studies.

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

Retrieved on: 
Wednesday, May 11, 2022

LEXINGTON, Mass., May 11, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that it will present four abstracts highlighting the company's GeneRide technology in preclinical hereditary tyrosinemia type 1 (HT1) models and optimized adeno-associated virus (AAV) manufacturing processes during the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting, held May 16-19, 2022, in Washington D.C. and virtually.

Key Points: 
  • LogicBio will present preclinical data from LB-401, its development candidate for the treatment of HT1.
  • The company believes that its optimized transfection process, which harnesses LogicBio's mAAVRx system, has the potential to significantly reduce per patient manufacturing costs.
  • LogicBio's downstream process improvements were made to accommodate the increased yield resulting from the company's optimized transfection process.
  • Securities and Exchange Commission(SEC) onMarch 4, 2022, and other filings that LogicBio may make with theSECin the future.

Rare Insight: A New Approach Optimizes Hepatoblastoma Cancer Treatment

Retrieved on: 
Monday, February 14, 2022

Hepatoblastoma is a rare childhood liver cancer, usually seen within the first three years of a childs life with 50 to 70 cases occurring in the U.S. each year.

Key Points: 
  • Hepatoblastoma is a rare childhood liver cancer, usually seen within the first three years of a childs life with 50 to 70 cases occurring in the U.S. each year.
  • The risk assessment process, called risk stratification, has the potential to improve success rates for children undergoing hepatoblastoma treatment.
  • In 2016, leading hepatoblastoma researchers from around the world created the Childrens Hepatic tumors International Collaboration Hepatoblastoma Stratification (CHIC-HS).
  • This cancer, from being a pretty deadly cancer, is now highly curable in a lot of patients, says Dr. Mascarenhas.

Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiver™ for Early Liver Cancer Detection

Retrieved on: 
Monday, November 8, 2021

"As a result of rigorous scientific evaluations, these new findings underscore HelioLiver's potential to detect liver cancer early and ultimately save lives," said Justin Chen Li, U.S. Chief Executive Officer, Helio Health.

Key Points: 
  • "As a result of rigorous scientific evaluations, these new findings underscore HelioLiver's potential to detect liver cancer early and ultimately save lives," said Justin Chen Li, U.S. Chief Executive Officer, Helio Health.
  • "Through our partnership with Fulgent Genetics, we look forward to delivering new early cancer diagnostic technologies beginning with HelioLiver in the U.S. in the near future."
  • Helio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw.
  • doi:10.1053/j.gastro.2018.01.064
    View original content to download multimedia: https://www.prnewswire.com/news-releases/helio-health-and-fulgent-geneti...
    SOURCE Helio Health and Fulgent Genetics, Inc.

Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting

Retrieved on: 
Thursday, September 16, 2021

The preclinical findings we have reported with ACT-903 validates our approach and we look forward to advancing this program into the clinic.

Key Points: 
  • The preclinical findings we have reported with ACT-903 validates our approach and we look forward to advancing this program into the clinic.
  • Alpha Cancer Technologies, Inc. is an emerging biotechnology company with products under development in immunotherapy (Inflammatory Bowel Disease, Multiple Sclerosis, Myasthenia Gravis, Hashimoto) and immuno-oncology.
  • ACTs immuno-oncology products target AFP receptors expressed on almost all solid and liquid tumors and immune suppressor cells but absent on normal cells.
  • This approach offers the benefits of much lower toxicity and greater efficacy compared to conventional chemotherapy and other targeted therapies.

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer

Retrieved on: 
Wednesday, July 21, 2021

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Key Points: 
  • Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.
  • The GPC3 protein is also expressed in other solid tumors including ovarian and lung cancer.
  • With ET140203, the ARTEMIS receptor targets an alpha fetoprotein (AFP)-peptide/HLA-A2 complex found on liver cancer cells using a TCR-mimic antibody.
  • Eureka Therapeutics, Inc. is a privately held clinical-stage biotechnology company focused on developing novel T cell therapies to treat cancers.

Epresspack, the Digital Newsroom Publisher, Signs a Joint Venture with Agence France-Presse (AFP) and Launches MediaConnect, a Unique Service in France

Retrieved on: 
Wednesday, May 26, 2021

The result of a joint venture between Epresspack and AFP, this large-scale newsroom is housed within an eponymous AFP subsidiary of which Epresspack is a shareholder.

Key Points: 
  • The result of a joint venture between Epresspack and AFP, this large-scale newsroom is housed within an eponymous AFP subsidiary of which Epresspack is a shareholder.
  • More specifically, the platform centralises and archives press releases (texts, images, videos, graphics, etc.)
  • Simplicity, trust and community are the hallmarks of this innovative newsroom, which offers an intuitive, responsive and secure experience for senders and receivers alike.
  • "We are very proud of our technological, commercial and financial partnership with this global news agency," explains Antoun Sfeir, CEO and founder of Epresspack.

Epresspack, the Digital Newsroom Publisher, Signs a Joint Venture with Agence France-Presse (AFP) and Launches MediaConnect, a Unique Service in France

Retrieved on: 
Wednesday, May 26, 2021

The result of a joint venture between Epresspack and AFP, this large-scale newsroom is housed within an eponymous AFP subsidiary of which Epresspack is a shareholder.

Key Points: 
  • The result of a joint venture between Epresspack and AFP, this large-scale newsroom is housed within an eponymous AFP subsidiary of which Epresspack is a shareholder.
  • More specifically, the platform centralises and archives press releases (texts, images, videos, graphics, etc.)
  • Simplicity, trust and community are the hallmarks of this innovative newsroom, which offers an intuitive, responsive and secure experience for senders and receivers alike.
  • "We are very proud of our technological, commercial and financial partnership with this global news agency," explains Antoun Sfeir, CEO and founder of Epresspack.

Helio Health Announces China NMPA Acceptance of Registration Application for Helio Liver Test

Retrieved on: 
Wednesday, March 24, 2021

IRVINE, Calif., March 24, 2021 /PRNewswire/ -- Helio Health , an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the China National Medical Products Administration (NMPA) has accepted the Company's registration application for its Helio Liver Test, a cell-free DNA (cfDNA) methylation blood test for the detection of hepatocellular carcinoma (HCC) or liver cancer.

Key Points: 
  • IRVINE, Calif., March 24, 2021 /PRNewswire/ -- Helio Health , an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced the China National Medical Products Administration (NMPA) has accepted the Company's registration application for its Helio Liver Test, a cell-free DNA (cfDNA) methylation blood test for the detection of hepatocellular carcinoma (HCC) or liver cancer.
  • The study evaluated 1,093 individuals in China with HCC and benign liver diseases as well as healthy controls.
  • "We look forward to working with the Chinese regulatory authorities to advance registration of the Helio Liver Test in China and we plan to share the encouraging details of the VICTORY trial at a later date."
  • The Helio Liver Test was validated in an independent cohort of 631 subjects, including patients with HCC (n=291) and age-matched healthy controls (n=340), compared to serum alpha-fetoprotein (AFP) alone, a well-known marker for liver cancer.